Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the year 2018.
David Veitch, Chief Executive Officer, said: "We continue to make great progress establishing Zevtera and in particular Cresemba, as global brands. We are very pleased with the strong sales performance in 2018. We have also significantly strengthened our pre-clinical and clinical oncology pipeline through in-licensing transactions. The encouraging interim derazantinib results in the registrational phase 2 study and the recently announced collaboration with Roche support the significant potential value in intrahepatic cholangiocarcinoma and urothelial cancer."